# Hepatology Overview: A Student Handout for PA/Medical Students ## Learning Objectives By the end of this session, you should be able to: 1. **Recognize** the major etiologies of chronic liver disease and their distinguishing features 2. **Interpret** liver function tests (LFTs) and hepatic synthetic markers 3. **Use** non-invasive fibrosis assessment tools (FIB-4, VCTE, MRE) to stage liver disease 4. **Explain** the pathophysiology of major complications (portal hypertension, ascites, hepatic encephalopathy) 5. **Discuss** evidence-based management of chronic liver disease 6. **Identify** when to refer patients to specialist hepatology care 7. **Understand** the role of newer medications (e.g., resmetirom for NASH) in modern hepatology ------------------------------------------------------------------------ ## Why This Matters for You - **Liver disease prevalence:** ~30% of U.S. adults have hepatic steatosis; ~2% have cirrhosis - **Growing burden:** Obesity, diabetes, alcohol, viral hepatitis → increasing liver disease rates - **Your role:** Early recognition, risk stratification, timely referral to hepatology - **Multidisciplinary care:** Nephrologists manage kidney dysfunction in cirrhosis; cardiologists manage HFpEF in NASH; you need to understand the full context ------------------------------------------------------------------------ ## The Diagnostic Approach: Laboratory Assessment First ### Liver Function Tests (LFTs) — What They Tell You | **Marker** | **Source** | **Elevation Pattern** | **Clinical Meaning** | |----|----|----|----| | **ALT (Alanine aminotransferase)** | Hepatocyte cytoplasm | Mild-moderate ↑ | Hepatocellular injury (viral, autoimmune, toxin) | | **AST (Aspartate aminotransferase)** | Hepatocyte mitochondria + cytoplasm | Variable | Hepatocellular injury; AST:ALT \>2 → alcoholic liver disease | | **ALP (Alkaline phosphatase)** | Bile duct epithelium | ↑ | Cholestatic or infiltrative disease | | **GGT (Gamma-glutamyl transferase)** | Bile duct epithelium | ↑ with ALP | Confirms hepatic origin of ALP elevation | | **Total Bilirubin** | Liver metabolism/excretion | ↑ | Impaired clearance or cholestasis | | **Direct Bilirubin** | Liver conjugation | ↑ | Intrahepatic or extrahepatic cholestasis | | **Albumin** | **Synthetic function** | ↓ | Advanced cirrhosis; poor prognosis | | **INR/PT** | **Synthetic function** | ↑ (prolonged) | Impaired clotting factor synthesis; cirrhosis | ### Key Pattern Recognition **Hepatocellular Pattern (ALT/AST ↑↑, ALP mild ↑):** - Viral hepatitis, autoimmune hepatitis, drug-induced injury, alcoholic hepatitis - ALT usually \>AST (except in alcoholic hepatitis where AST:ALT \>1.5) **Cholestatic Pattern (ALP/GGT ↑↑, ALT/AST mild ↑):** - Primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), drug toxicity, pregnancy - ALP ↑ confirmed by GGT **Mixed Pattern (Both ↑↑):** - Acute hepatitis, infiltrative disease, cirrhosis **Synthetic Dysfunction (↓ Albumin, ↑ INR):** - **Indicates advanced disease:** Cirrhosis or fulminant hepatic failure - Normal LFTs with low albumin/↑ INR = cirrhosis until proven otherwise ------------------------------------------------------------------------ ## Major Etiologies of Chronic Liver Disease ### 1. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) **Formerly NAFLD; new name emphasizes metabolic etiology, not absence of alcohol** **Epidemiology:** - Most common liver disease globally (~30% of adults) - Linked to obesity (BMI ≥25), diabetes, hypertension, dyslipidemia **Pathophysiology:** - Hepatic triglyceride accumulation (\>5% of liver weight) - Steatohepatitis (MASH) = steatosis + inflammation + fibrosis - Risk: Progression to cirrhosis in 15-20% over 10 years **Diagnosis:** - Imaging (ultrasound, CT, MRI) showing steatosis - ≥1 cardiometabolic risk factor - Exclusion of other liver diseases **Risk Stratification:** - **FIB-4 score** = (Age × AST) / (Platelets × √ALT) - FIB-4 \<1.3 (or \<2.0 if age \>65): Low risk - FIB-4 1.3-2.67: Intermediate; needs second-line testing - FIB-4 \>2.67: High risk; likely advanced fibrosis - **VCTE (FibroScan):** \<8 kPa = low risk; \>12 kPa = high risk - **MRE:** Most accurate non-invasive method; thresholds 3.0-5.0 kPa by fibrosis stage **Management:** - **Weight loss:** 7-10% for improvement; \>10% for regression - **Exercise:** 150 min moderate-intensity weekly - **Diet:** Mediterranean or low-carbohydrate patterns - **Medications:** Resmetirom (recently FDA approved for MASH with F1B-F3 fibrosis) **Resmetirom (Rezdiffra) — New Game-Changer:** - **Mechanism:** Selective thyroid hormone receptor-β (THR-β) agonist - **Effect:** Enhances fatty acid oxidation; decreases steatosis; improves fibrosis - **MAESTRO-NASH trial:** 26-30% achieved NASH resolution + fibrosis improvement (vs. 9-14% placebo) - **Side effects:** Diarrhea (30%), nausea (20%), abdominal pain (15%) — mostly mild, transient - **Starting dose:** 80 mg daily; can titrate to 100 mg - **Indication:** F1B-F3 fibrosis (biopsy-confirmed NASH) ------------------------------------------------------------------------ ### 2. Alcoholic Liver Disease (ALD) **Epidemiology:** - Second most common cause of cirrhosis (after MASLD) - Requires heavy alcohol use (typically \>60 g/day for men, \>40 g/day for women, for years) - Risk of cirrhosis: ~10-15% of heavy drinkers **Spectrum:** - **Fatty liver:** Usually reversible with abstinence - **Alcoholic hepatitis:** Acute inflammation; mortality 30-40% if severe - **Cirrhosis:** Advanced, often irreversible; high decompensation risk **Key Laboratory Finding:** - **AST:ALT ratio \>2.0** (AST elevated more than ALT, unlike viral hepatitis) - AST typically \<300 U/L (higher values suggest ATN or other cause) **Management:** - **Alcohol cessation:** Absolute requirement; brief intervention, counseling, pharmacotherapy - **Nutritional support:** BCAA supplementation for sarcopenia - **Corticosteroids:** Considered in severe acute alcoholic hepatitis (MELD \>11 or hepatic encephalopathy) - **Liver transplantation:** Available for carefully selected patients (6 months sobriety usually required) ------------------------------------------------------------------------ ### 3. Viral Hepatitis B and C #### Hepatitis B (Chronic) - **Prevalence:** ~296 million chronically infected globally - **Transmission:** Sexual, vertical, needle-stick, percutaneous - **Diagnosis:** HBsAg+; HBeAg/HBeAb; HBV DNA quantification - **Natural history:** 95% of adults clear acute infection; 5-10% chronic - **Treatment:** Nucleos(t)ide reverse transcriptase inhibitors (NRTIs) — entecavir, tenofovir - **Cure:** Not achievable; goal is sustained virological response (undetectable HBV DNA) #### Hepatitis C (Chronic) - **Prevalence:** ~58 million chronically infected - **Major advance:** Direct-acting antivirals (DAAs) with **\>95% cure rate** - **Treatment:** 8-12 week courses of DAA combinations - **Post-cure:** Monitor for HCC; fibrosis may regress - **Special scenario:** HCV + HBV coinfection → higher HCC risk; treat both ------------------------------------------------------------------------ ### 4. Autoimmune Liver Diseases #### Autoimmune Hepatitis (AIH) - **Mechanism:** T-cell mediated hepatocyte destruction - **Diagnosis:** Elevated transaminases + ↑ immunoglobulins (IgG) + positive autoantibodies (ANA, ASMA, anti-LKM) - **Treatment:** Corticosteroids + azathioprine - **Prognosis:** Good with treatment; 80% remission rate #### Primary Biliary Cholangitis (PBC) - **Mechanism:** Autoimmune destruction of small bile ducts - **Diagnosis:** ↑ ALP + ↑ GGT + anti-mitochondrial antibody (AMA) - **Treatment:** Ursodeoxycholic acid (UDCA); obeticholic acid if inadequate UDCA response - **Prognosis:** Slow progression; median transplant-free survival 15-20 years #### Primary Sclerosing Cholangitis (PSC) - **Mechanism:** Progressive fibro-obliteration of bile ducts - **Association:** 70% have inflammatory bowel disease (IBD) - **Diagnosis:** MRCP showing “beads on string” appearance - **Treatment:** Limited; UDCA benefits unclear; monitor for cholangiocarcinoma - **Prognosis:** Variable; 10-15 year median transplant-free survival from diagnosis ------------------------------------------------------------------------ ## Non-Invasive Assessment of Fibrosis: The Shift Away From Biopsy ### Why Non-Invasive Testing? - **Liver biopsy:** Invasive, painful, risk of bleeding, sampling error (small sample ≠ whole liver) - **Non-invasive methods:** Accurate, repeatable, safe, cheaper than biopsy ### FIB-4 Index (Calculation & Interpretation) **Formula:** FIB-4 = (Age × AST) / (Platelet count × √ALT) **Interpretation (HCV population):** - **FIB-4 \<1.3:** Low probability advanced fibrosis; NPV 95% (if negative, unlikely F3-F4) - **FIB-4 1.3-2.67:** Intermediate; need second-line test (elastography, biomarkers) - **FIB-4 \>2.67:** High probability advanced fibrosis; PPV 65% **Age-Adjusted Thresholds (for age \>65):** - Use threshold 2.0 (low risk) and 3.25 (high risk) to reduce false positives **Advantages:** Free, requires only routine labs, widely validated **Limitations:** Less accurate in cirrhosis; affected by inflammation, hemolysis ### Vibration-Controlled Transient Elastography (VCTE / FibroScan) **What It Does:** - Measures **liver stiffness** via shear wave propagation - Stiff liver (fibrosis/cirrhosis) = faster wave travel = higher reading **Interpretation (kPa):** - **\<8 kPa:** No significant fibrosis (F0-F1) - **8-12 kPa:** Intermediate; need additional testing - **\>12 kPa:** Likely advanced fibrosis or cirrhosis **Advantages:** - Point-of-care; rapid; operator-dependent but reproducible with experience - Can be repeated serially to track progression **Limitations:** - Fails in obesity (BMI \>30) — XL probe helps but still limited - Affected by inflammation, congestion, ascites - No direct visualization of anatomy ### Magnetic Resonance Elastography (MRE) **Advantages:** - **Most accurate** non-invasive method for fibrosis - Not affected by obesity, operator, inflammation as much - Measures stiffness over entire liver **Interpretation (Standardized Cutoffs):** - **\<3.0 kPa:** F0 (no fibrosis) - **3.0-3.5 kPa:** F1 (mild) - **3.5-4.0 kPa:** F2 (significant) - **4.0-5.0 kPa:** F3 (advanced) - **\>5.0 kPa:** F4 (cirrhosis) **Limitations:** - Expensive; not universally available; requires MRI (contraindications possible) - Longer acquisition time ### Biomarker Panels **FIB-4:** Discussed above; free **NAFLD Fibrosis Score (NFS):** Age, BMI, diabetes, AST:ALT ratio, platelets, albumin **Enhanced Liver Fibrosis (ELF):** Proprietary blood test measuring hyaluronic acid, TIMP-1, PIIINP **APRI:** AST-to-platelet ratio; simple but lower performance **Combination Algorithms:** - **Agile 3+:** VCTE + clinical parameters for F3 detection - **Agile 4:** Optimized for cirrhosis (F4) detection - **MEFIB:** MRE + FIB-4 score for enhanced accuracy ------------------------------------------------------------------------ ## Portal Hypertension: The Complication Hub ### Pathophysiology - **Cirrhosis → structural resistance to blood flow** through liver - **Portal pressure rises** (normally \<12 mmHg; cirrhosis often \>15-20 mmHg) - **Splanchnic vasodilation → portosystemic shunts form** → blood bypasses liver - **Cascade of complications:** Variceal bleeding, ascites, hepatic encephalopathy, HRS ### Non-Invasive Assessment of Portal Hypertension **Baveno VII Criteria:** Risk stratify to avoid unnecessary endoscopy **Criteria for LOW variceal bleeding risk (no endoscopy needed):** - Platelet count \>150,000 - VCTE \<20 kPa - If both met: Variceal bleeding risk \<5%; can avoid screening endoscopy **Criteria for HIGH risk (endoscopy recommended):** - Platelet count ≤150,000 OR VCTE ≥20 kPa - Proceed to upper endoscopy for variceal assessment ### Major Complications **1. Variceal Bleeding:** - First bleed mortality: 15-20% - Prophylaxis: Beta-blockers reduce bleeding risk by ~40% - Acute treatment: Endoscopic variceal ligation (EVL) \>90% success **2. Ascites:** - Define as fluid accumulation in peritoneal cavity - Grade 1: Ultrasound only - Grade 2: Mild physical examination findings - Grade 3: Clinically apparent; impairs respiratory function - Management: Sodium restriction (\<2 g/day) + diuretics (spironolactone, furosemide) **3. Hepatic Encephalopathy:** - Neuropsychiatric dysfunction from portal hypertension + liver failure - Grades 1-4 (subtle confusion → deep coma) - Treatment: Lactulose (osmotic laxative), rifaximin (non-absorbed antibiotic) **4. Spontaneous Bacterial Peritonitis (SBP):** - Bacterial infection of ascites without source - Diagnosis: \>250 PMN/μL in ascitic fluid culture positive - Treatment: Third-generation cephalosporin (ceftriaxone) - Prophylaxis: Norfloxacin in high-risk patients ------------------------------------------------------------------------ ## Management Principles: General Approach ### Etiology-Specific Therapy - **Viral hepatitis:** Antivirals (DAA for HCV, NRTIs for HBV) - **Autoimmune:** Immunosuppression - **MASLD:** Weight loss, medications (resmetirom) - **Alcoholic:** Abstinence, nutritional support ### Universal Recommendations - **Lifestyle:** Alcohol cessation, weight loss, exercise, Mediterranean diet - **Vaccination:** Hepatitis A & B (if non-immune), influenza, pneumococcal, COVID-19 - **Surveillance:** HCC screening (ultrasound ± AFP every 6 months if cirrhosis) - **Medication safety:** Avoid hepatotoxins (acetaminophen \>2 g/day in cirrhosis, NSAIDs) ### Monitoring for Decompensation - Regular assessment for ascites, encephalopathy, bleeding - Serial albumin, INR, bilirubin (synthetic function) - MELD score tracking (predicts transplant need) - FIB-4 or VCTE annually to track fibrosis progression ------------------------------------------------------------------------ ## Referral Criteria: When to Send to Hepatology **Refer immediately if:** - **Cirrhosis diagnosed** (any etiology) - **Evidence of portal hypertension** (ascites, varices, splenomegaly, platelet \<100) - **Hepatic encephalopathy** present - **Child-Pugh B or C** class cirrhosis - **MELD score \>15** (likely transplant candidate) **Refer semi-urgently (weeks) if:** - **Advanced fibrosis** (FIB-4 \>2.67 or VCTE \>12 kPa) without cirrhosis - **Significant ALT/AST elevation** without clear etiology - **Chronic viral hepatitis** needing antiviral therapy - **Autoimmune hepatitis** suspected **Refer electively (routine referral) if:** - **MASLD** with obesity/metabolic risk factors requiring risk stratification - **Recent HCV diagnosis** (for DAA therapy evaluation) - **Compensated cirrhosis** for baseline assessment/surveillance planning ------------------------------------------------------------------------ ## Key Clinical Pearls 1. **AST:ALT ratio is your friend.** \>2:1 with AST \<300 = alcoholic liver disease. Think alcohol use disorder. 2. **FIB-4 is free and powerful.** Use it as a first-line tool to identify high-risk patients needing further workup. 3. **Liver biopsy is rarely needed today.** Non-invasive tests (FIB-4, VCTE, MRE) are accurate and safe. Biopsy is reserved for diagnostic uncertainty. 4. **MASLD is not benign.** It’s the most common liver disease globally and a leading cause of HCC. Risk-stratify appropriately. 5. **Resmetirom changes the game for NASH.** First medication approved specifically for MASH with fibrosis; solid efficacy in trials. 6. **Portal hypertension drives complications.** Once VCTE \>20 kPa or platelets drop, expect varices, ascites, encephalopathy. Screen and prevent. 7. **Early recognition saves lives.** Many cirrhotic patients present after variceal bleed or encephalopathy. Earlier referral for endoscopy/imaging could prevent this. 8. **Transplant evaluation is timely intervention.** MELD \>15 or decompensation = likely transplant candidate. Don’t miss the window. ------------------------------------------------------------------------ ## Summary Table: Major Liver Diseases at a Glance | **Disease** | **Epidemiology** | **Key Lab Finding** | **Diagnosis** | **Treatment Goal** | |----|----|----|----|----| | **MASLD** | 30% population; obesity/DM | ↑ ALP, normal LFTs early | Imaging + risk factors | Weight loss; resmetirom for MASH | | **Alcoholic LD** | 2% population; heavy EtOH use | AST:ALT \>2, AST \<300 | Clinical hx; exclude others | Abstinence; transplant if severe | | **HBV** | 296M globally; sexual/vertical | HBsAg+; HBV DNA | Serology; HBV DNA quantitation | NRTI therapy; suppress replication | | **HCV** | 58M globally; IVDU/transfusion | Anti-HCV+; HCV RNA | Serology; HCV RNA quantitation | DAA therapy; cure (\>95%) | | **AIH** | 1:100,000; autoimmune | ↑↑ ALT/AST; ↑ IgG; ANA+ | Serology; biopsy if uncertain | Corticosteroids; remission | | **PBC** | 40:100,000; women; autoimmune | ↑↑ ALP/GGT; AMA+ | Serology; imaging | UDCA; obeticholic acid | | **PSC** | 15:100,000; associated IBD | ↑↑ ALP/GGT; MRCP | MRCP imaging | Limited; monitor for CCA | ------------------------------------------------------------------------ ## Practice Questions ### Question 1: Laboratory Interpretation A 55-year-old man with no prior liver disease presents with ALT 280, AST 140, ALP 95, bilirubin 1.2, albumin 3.8, INR 1.0. Ultrasound shows steatosis without cirrhosis. **Most likely diagnosis?** A. Hepatitis C B. Alcoholic liver disease C. Metabolic dysfunction-associated steatotic liver disease (MASLD) D. Primary biliary cholangitis **Answer:** C. **ALT\>AST pattern with mild-moderate elevation, normal synthetic markers, steatosis on imaging, no jaundice = MASLD.** In alcoholic liver disease, AST:ALT would be \>2. HCV typically causes lower transaminase elevations. PBC would show high ALP. This is straightforward MASLD. ------------------------------------------------------------------------ ### Question 2: Risk Stratification A 62-year-old woman with MASLD (steatosis on imaging, BMI 32, hypertension) has labs: age 62, AST 48, ALT 65, platelet 240. **Calculate her FIB-4 index and interpret risk:** FIB-4 = (62 × 48) / (240 × √65) = 2976 / (240 × 8.06) = 2976 / 1934 = **1.54** **Interpretation?** A. Low risk; no further workup needed B. Intermediate risk; needs VCTE or MRE C. High risk; likely cirrhosis D. Very high risk; immediate transplant evaluation **Answer:** B. FIB-4 = 1.54 = **Intermediate risk (falls between 1.3-2.67).** This patient needs second-line testing (VCTE or MRE) to better characterize her fibrosis stage. She’s not high-risk yet, but not low-risk either. Don’t stop at FIB-4; continue workup. ------------------------------------------------------------------------ ### Question 3: Clinical Management A 50-year-old with compensated cirrhosis (VCTE 18 kPa, platelet 160) is found to have esophageal varices (not bleeding). No ascites or encephalopathy. **Best management:** A. Upper endoscopy with variceal ligation (EVL) B. Observe; no intervention needed C. Start beta-blocker (propranolol or carvedilol) D. Immediate hospitalization; prepare for blood transfusion **Answer:** C or A (both are correct depending on context). **At minimum, start beta-blocker prophylaxis** (reduces first-bleed risk ~40%). **EVL is also indicated** for documented varices in high-risk patients or as elective prophylaxis. Optimal is both: beta-blocker + EVL. Observation alone is inadequate; this patient needs intervention. No bleeding yet, so hospitalization not needed. ------------------------------------------------------------------------ ## References & Further Reading 1. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. [PubMed](https://pubmed.ncbi.nlm.nih.gov/36727674/) 2. Jophlin LL, Singal AK, Bataller R, et al. ACG Clinical Guideline: Alcohol-Associated Liver Disease. Am J Gastroenterol. 2024;119(1):30-54. [PubMed](https://pubmed.ncbi.nlm.nih.gov/38174913/) 3. de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959-974. [PubMed](https://pubmed.ncbi.nlm.nih.gov/35120736/) 4. Harrison SA, Bedossa P, Guy CD, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497-509. [PubMed](https://pubmed.ncbi.nlm.nih.gov/38324483/) 5. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 2021;75(3):659-689. [PubMed](https://pubmed.ncbi.nlm.nih.gov/34166721/) ------------------------------------------------------------------------ *Created for PA/Medical Student Education in Hepatology. Last updated February 2026.* --- [Website version](https://urinenephrology.org/student-resources/hepatorenal/hepatology-overview-student-handout.html) · Markdown synchronized October 3, 2026.